Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $16 price target.
June 27, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Longboard Pharmaceuticals and maintained a $16 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald's analyst Alethia Young indicates a positive outlook for Longboard Pharmaceuticals. The maintained $16 price target suggests that the stock is expected to perform well in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100